

Reference Number: FOIAH2425/613
From: Private Individual
Date: 29 January 2025
Subject: Patients treated by dermatology with Dupilumab in the latest four months (September to December 2024)

Q1 For patients treated by the dermatology department with Dupilumab in the latest four months (September to December 2024), could you please tell us:

- how many patients were treated in the previous 4-month period (May to August 2024) with Dupilumab?
- how many patients were treated in the previous 4-month period (May to August 2024) with any of the following advanced therapies: abrocitinib, baricitinib, tralokinumab, upadacitinib and lebrikizumab?
- how many patients were treated in the previous 4-month period (May to August 2024) with any of the following immunosuppressants: Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?
- how many patients were treated in the previous 4-month period (May to August 2024) with any other treatment? (e.g. Acitretin, Alitretin, Pimecrolimus, Tacrolimus, oral corticosteroids , topical steroids)

A1 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.

Q2 For patients treated by the dermatology department with Dupilumab in the four months from May to August 2024, could you please let us:

- how many patients were treated in the subsequent 4-month period (September to December 2024) with Dupilumab?
- how many patients were treated in the subsequent 4-month period (September to December 2024) with any of the following advanced therapies: abrocitinib, baricitinib, tralokinumab, upadacitinib and lebrikizumab?
- how many patients were treated in the subsequent 4-month period (September to December 2024) with any of the following immunosuppressants: Methotrexate, Ciclosporin, Mycophenolate or Azathioprine?
- how many patients were treated in the subsequent 4-month period (September to December 2024) with any other treatment? (e.g. Acitretin, Alitretin, Pimecrolimus, Tacrolimus, oral corticosteroids , topical steroids)

A2 Information not held – the Trust does not routinely collate or hold this information centrally as part of its management or performance data. In order to confirm treatment following medication being dispensed, the Trust would be required to access personal data of the individuals and as such the data is exempt under Section 40: Personal data.